Repeated allergen challenge has been shown to increase the role of Rho-kinase in airway smooth muscle (ASM) contraction. We considered the possibility that active allergic sensitization by itself, i.e. without subsequent allergen exposure, could be sufficient to enhance Rho-kinase-mediated ASM contraction. To this aim guinea pigs were actively IgE-sensitized to ovalbumin (OA), using Al(OH) 3 as adjuvant. Contractile responsiveness to G q -coupled receptor agonists (methacholine, histamine or PGF 2 ) was investigated in tracheal rings. No effect of sensitization was observed on basal-and methacholine-induced myogenic tone. In contrast, potency of histamine and PGF 2 increased, i.e. EC 50 decreased, after OA-sensitization by 2.6-and 4.7-fold, respectively, without effect on maximal contraction (E max ). Basal tone in preparations from both control and OA-sensitized animals was strongly decreased in the presence of the Rhokinase inhibitor Y-27632 (1µM). In control preparations, the E max and potency of histamine were unaffected by Y-27632, but were decreased for PGF 2 (by 38.2 % and 2.0-fold, respectively). However, in preparations from OA-sensitized animals, Y-27632 induced a significant reduction in E max (33.5 %) and potency (2.3-fold) of histamine and of PGF 2 (48.3 % and 6.6-fold, respectively), normalizing the OA-sensitization-induced increase in sensitivity toward these agonists. We also investigated the contribution of Rho-kinase in vivo by measuring airway responsiveness toward inhaled histamine in permanently instrumented, unanaesthetized control and OA-sensitized guinea pigs. Treatment with Y-27632 by inhalation (5 mM, nebulizer concentration) decreased airway responsiveness toward histamine both in control and OA-sensitized animals. However, the histamine PC 100 ratio pre/post Y-27632 inhalation was significantly smaller in OA-sensitized animals as compared to control animals, indicating an enhanced contribution of Rho-kinase. We also found that the expression of RhoA, an upstream activator of Rho-kinase, was significantly increased (2.6-fold) in lung homogenates of OA-sensitized guinea pigs compared to control animals, as determined by Western analysis. In conclusion, the results show a receptor-dependent role of Rhokinase in agonist-induced ASM contraction. The contribution of Rho-kinase to contractile airway responsiveness, both in vivo and ex vivo, is augmented after active allergic sensitization, presumably as a consequence of increased expression of RhoA. Inhibition of the RhoA/Rho-kinase pathway may be considered a useful pharmacotherapeutical target in allergy and asthma.
Introduction
Smooth muscle contraction is governed to an important extent by the phosphorylation level of myosin light chain (MLC) [1] . MLC phosphorylation may be caused by an increase in intracellular Ca 2+ -concentration ( [Ca 2+ ] i ), via formation of Ca 2+ -calmodulin and subsequent activation of myosin light chain kinase (MLCK). However, it has been shown that [Ca 2+ ] i does not always parallel the level of MLC phosphorylation and contraction. The level and the extent of MLC phosphorylation are determined by the ratio of MLCK (MLC-phosphorylation) to MLCP (MLC-dephosphorylation) activities [2] . Hence, inhibition of MLC phosphatase (MLCP), e.g. after agonist induced activation of the RhoA/Rho-kinase pathway [3, 4] , can effectively enhance MLC phosphorylation at a fixed [Ca 2+ ] i , thereby contributing to an augmented level of contraction. Indeed, Rhokinase has been reported to contribute to smooth muscle contraction [5] [6] [7] by such an increased sensitivity of the contractile apparatus toward Ca 2+ , also referred to as Ca 2+ -sensitization [3] .
Contractility of airway smooth muscle (ASM) preparations obtained from patients suffering from asthma has been reported increased in some [8] [9] [10] , but not all patients [11] [12] [13] . It has also been demonstrated that passive allergic sensitization in vitro as well as active (ragweed) sensitization in vivo may increase contractile responsiveness of human and canine ASM preparations, respectively [14] [15] [16] .
Acetylcholine-induced, Rho-mediated Ca 2+ -sensitization of bronchial smooth muscle has been found to be increased in repeatedly allergen-challenged rats [17] , and since the specific Rho-kinase inhibitor Y-27632 did suppress AHR in mice repeatedly challenged with ovalbumin (OA) after sensitization in the absence and presence of respiratory syncytial virus infection [18] , changes in contraction mediated by the Rho/Rho-kinasepathway could contribute to the development of AHR under these conditions.
In the present study, we considered the possibility that active allergic sensitization by itself, i.e. without subsequent allergen exposure, may already induce an enhanced contribution of Rho-kinase to contractile responsiveness of guinea pig airways, both in vivo and ex vivo.
Methods

Animals
Outbred specified pathogen-free male Dunkin Hartley guinea pigs (Harlan, Heathfield, U.K.) were used. The animals were divided into two groups, i.e. control animals and OA-sensitized animals. These animals were actively IgE-sensitized to OA as described previously [19] . In short, 0.5 ml of an allergen solution containing 100 g ml -1 OA and 100 mg ml -1 Al(OH) 3 in saline was injected intraperitoneally, while another 0.5 ml was divided over seven intracutaneous injection sites in the proximity of lymph nodes in the paws, lumbar regions and the neck. Sensitization with OA induces both IgG 1 -and IgEclass antibodies in the guinea pig [20] . However, using Al(OH) 3 as adjuvant, a shift toward IgE-class antibodies is induced [21] , resulting in relatively high IgE titers as determined by the passive cutaneous anaphylaxis (PCA) test [22] . The animals were used experimentally in weeks 4 to 8 after sensitization. The animals were group-housed in individual cages in climate controlled animal quarters and given water and food ad libitum, while a 12-h on/12-h off light cycle was maintained. All protocols described in this study were approved by the University of Groningen Committee for Animal Experimentation.
Isometric tension measurements
After a sharp blow on the head and rapid exsanguination the trachea was removed and transferred to Krebs-Henseleit (KH) buffer solution (composition in mM: NaCl 117.5, KCl 5.6, MgSO 4 1.18, CaCL 2 2.5, NaH 2 PO 4 1.28, NaHCO 3 25.00 and D-glucose 5.55; pregassed with 95% O 2 and 5% CO 2 ; pH 7.4) at 37 °C. The trachea was carefully prepared free of mucosa and connective tissue. Single open-ring tracheal preparations were mounted for isometric recording, using Grass FT-03 transducers, in 20 ml waterjacketed organ baths (37 °C) containing KH solution. During a 90 min equilibration period, with washouts every 30 min, resting tension was gradually adjusted to 0.5 g. Subsequently, the preparations were precontracted with 20 and 40 mM KCl. Following two wash-outs, maximal relaxation was established by the addition of 0.1 M isoprenaline and tension was re-adjusted to 0.5 g, immediately followed by two changes of fresh KH-buffer. After another equilibration period of 30 min, cumulative concentration response curves (CRCs) were constructed to stepwise increasing concentrations of methacholine (1 nM-100 M), histamine (1 nM -100 M) or PGF 2 (1 nM -10 M). When maximal agonist-induced contraction was obtained, the tracheal rings were washed several times and maximal relaxation was established using isoprenaline. When used, the Rho-kinase inhibitor Y-27632 (1 M) was applied to the organ bath 30 min before agonist addition. This concentration has been shown to be effective and selective in smooth muscle [7, 23] 
Measurement of airway function
To investigate the contribution of Rho-kinase to airway responsiveness in vivo, airway function was assessed of nonsensitized (control) and actively OA-sensitized unrestrained guinea pigs, by measurement of pleural pressure (P pl ) as described previously [24] . In short, a small saline-filled balloon-catheter was surgically implanted (2 weeks after sensitization) inside the thoracic cavity. The free end of the catheter was driven subcutaneously to the neck of the animal, where it was exposed and attached permanently. Via an external saline-filled canula the pleural balloon was connected to a pressure transducer (Ohmeda DTX, SpectraMed, Bilthoven, the Netherlands), enabling continuous measurement of P pl changes (in cm H 2 O). We have previously found that changes in P pl are linearly correlated to changes in airway resistance and hence can be used as a sensitive index for bronchoconstriction [24] .
Provocation procedure
Histamine provocations were performed by inhalation of aerosolized solutions, produced by a DeVilbiss nebulizer (type 646; DeVilbiss, Somerset, PA, USA), with an airflow of 8 l min -1 resulting in an output of 0.33 ml min -1 . Provocations were carried out in a perspex cage (internal volume, 9 l) in which the guinea pigs could move freely. Before the start of the experiment, the animals were habituated to the experimental conditions and the provocation procedures on two sequential days at least one week after surgery, when preoperative weight was restored. On the first day, the animals were placed in the provocation cage unconnected to the pressure transducer. After an adaptation period of 30 min, three consecutive provocations with saline were performed, each exposure lasting 3 min and separated by a 7 min interval. The next day, this procedure was repeated with the animals connected to the measurement system. During the experimental protocol following the habituation procedure, all provocations were preceded by a 30 min adaptation period, followed by one control provocation with saline (3 min) as already described. To assess the airway reactivity for histamine, provocations with this agonist were performed starting with a 25 g ml -1 solution in saline, followed by increasing dosage steps of 25 g ml -1 . Histamine provocations lasted 3 min, separated by 7 min intervals. Histamine was aerosolized until P pl was increased by more than 100 % above baseline for at least 3 consecutive minutes. P pl returned to baseline value within 15 min after the last histamine provocation. The concentration histamine causing a 100 % increase of P pl (PC 100 -value) was derived by linear intrapolation of the concentration-P pl curve and was used as an index for airway reactivity toward histamine. Since we were interested in the effect of active allergic sensitization on the contribution of Rho-kinase to airway responsiveness, we determined the effect of Y-27632 inhalation on histamine PC 100 -values both in nonsensitized and OA-sensitized animals. To this aim, a 5 mM solution of Y-27632 in saline was aerosolized for 5 min, thirty minutes after the assessment of the basal histamine PC 100 ; saline inhalation was used as a control. After a resting period of 20 min, the next histamine PC 100 measurement was started. Changes in airway responsiveness toward histamine were expressed as the ratio PC 100 pre/post Y-27632 inhalation.
Western blotting for RhoA
Lung homogenates from control and OA-sensitized guinea pigs were prepared by pulverizing tissue under liquid nitrogen and subsequent sonification in homogenization buffer (composition in mM: NaCl 150.0, Tris HCl 10.0, 2-glycerophosphoric acid 5.0, EGTA 2.0, DTT 2.0, PMSF 1.0, Na 3 VO4 1.0, NaF 1.0, pH 7.5, supplemented with 10 g.ml -1 leupeptin, 10 g.ml -1 aprotinin and 1 % Triton X-100). Protein content was determined according to Bradford (1976) . 50 g of protein per lane was separated on a 10 % polyacrylamide gel. Proteins were then transferred onto nitrocellulose membranes, which were blocked overnight at 4 o C in blocking buffer (composition: Tris 50.0 mM; NaCl 150.0 mM; dried milk powder 5 %). After two washes in wash buffer (composition: Tris 50.0 mM; NaCl 150.0 mM; Tween 20 0.1 %), membranes were incubated for 1 h at room temperature in primary antibody (anti-RhoA, Santa Cruz Biotechnology, 130 California, USA, diluted 1:250 in blocking buffer). After three washes, membranes were incubated in horseradish peroxidase labelled secondary antibody (anti-rabbit IgG, Cell Signalling Technology,Beverly, USA, diluted 1:2000 in blocking buffer) at room temperature for 1 h, followed by another three washes. Antibodies were then visualised by enhanced chemiluminescence. Photographs of blots were analyzed by densitometry (Totallab   tm   ) .
Data analysis
In isometric contraction experiments all curves were related to maximal histamineinduced contraction, as determined each time in at least two parallel preparations from the same animal, since no differences in maximal histamine-induced contraction were observed after active OA-sensitization. All data represent means ± s.e. mean from n separate experiments. Statistical significance of difference was determined by the Student's t-test for paired observations. Differences were considered significant when P<0.05. 
Materials
Results
In order to investigate the contractile properties of guinea pig ASM after active OAsensitization, we measured both basal and agonist-induced myogenic tone in intact nonpermeabilized tracheal smooth muscle preparations. Basal tone was defined as the resting tension compared to the maximal relaxation established with isoprenaline. No effect of OA-sensitization was observed on basal myogenic tone (Figure 1 ). In addition, maximal contraction (E max ) and potency (pEC 50 ) of methacholine were not different between preparations from control and OA-sensitized animals (E max = 2.21 ± 0.18 g and 2.14 ± 0.16 g respectively; pEC 50 = 6.62 ± 0.12 and 6.61 ± 0.09 respectively). However, potency of histamine and PGF 2 increased significantly after OA-sensitization, whereas no effect on E max was observed (Figure 2 ; Table 1 ).
-log[Histamine] (M) Similar effects of active allergic sensitization on histamine-induced contraction were found in epithelium-denuded preparations, indicating that OA-sensitization-induced differences have not been caused by epithelium derived factors/mediators (Table 2) . Considering the effect of OA-sensitization on histamine and PGF 2 -mediated contraction, we further focussed on these two agonists. To determine the contribution of Rho-kinase, we used the selective Rho-kinase inhibitor Y-27632 (1 M). In preparations from both control and OA-sensitized animals, basal tone was almost fully inhibited by Y-27632 (Figure1). In control preparations, treatment with Y-27632 had no significant effect on E max or pEC 50 of histamine (Figure 3a ; Tables  1,2 ). In contrast, treatment with Y-27632 significantly decreased E max and potency of PGF 2 in control tracheal preparations (Figure 3c ; Table 1 ). Remarkably, although treatment with Y-27632 had no effect on histamine-induced contraction in control preparations, Y-27632 induced a significant decrease in potency and E max of histamine in preparations from OA-sensitized animals (Figure 3b ; Tables  1,2) . Treatment with the Rho-kinase inhibitor also markedly decreased potency and E max of PGF 2 ( Figure 3d ; Table 1 ). Note that the OA-sensitization-induced increase in potency of histamine and PGF 2 was normalized in the presence of Y-27632. As shown in Figure 1 , Y-27632 strongly reduced basal tone. Since it could be imagined that reduction of basal tone by itself might affect the maximal response or potency of contractile agonists, separate experiments were performed using preparations from nonsensitized animals in which basal tone was decreased using indomethacin (3 µM). This treatment did not at all affect E max or potency of histamine. If original basal tone was then re-established using small additions of PGF 2 , potency or maximal contraction of histamine were not affected either (Figure 4 ). To establish whether the contribution of Rho-kinase to airway responsiveness is enhanced in vivo, we investigated the effects of treatment with Y-27632, given by inhalation (5 mM, nebulizer concentration) in permanently instrumented, freely moving guinea pigs. Y-27632-inhalation decreased the histamine-responsiveness both of nonsensitized and OA-sensitized animals. The histamine PC 100 ratio pre/post Y-27632 inhalation, however, was significantly smaller in OA-sensitized animals (0.47) as compared to control animals (0.60; Figure 5 ). To study the effects of OA-sensitization on RhoA-protein levels, we assessed the expression of RhoA in lung homogenates by Western analysis. As shown in Figure 6 , RhoA was expressed in lungs from both control and OA-sensitized animals. RhoAexpression was markedly increased (2.6-fold) after OA-sensitization (Figure 6 ), suggesting that the enhanced role of Rho-kinase to airway responsiveness after OAsensitization might be caused by augmented levels of RhoA. 
Discussion
Rho-mediated Ca 2+ -sensitization contributes to smooth muscle contraction under normal conditions [5, 6, 25] . However, evidence exists that Ca 2+ -sensitizing mechanisms may be primed by pathophysiological conditions. In vascular smooth muscle, increased activity of the Rho-kinase mediated pathway has been implicated in the genesis of enhanced vasoconstriction in spontaneously hypertensive rats [26] . Also in humans it has been shown that Rho-kinase could be involved substantially in the pathogenesis of increased peripheral vascular resistance in hypertension [27] . In addition, in patients with vasospastic angina, acetylcholine-induced coronary artery spasm was effectively prevented by the Rho-kinase inhibitor fasudil, whereas fasudil had a minimal effect on acetylcholine-induced vasoconstriction in nonspastic segments in these patients [28] .
This pathophysiology-primed role for Rho-kinase may also be important for airway diseases, since previous studies showed an augmented role of Rho-kinase in acetylcholine induced bronchial smooth muscle contraction after repeated allergen challenge in rats [17, 29] . Moreover, using the specific Rho-kinase inhibitor Y-27632, we currently demonstrate that the process of active allergic sensitization by itself is sufficient to induce an enhanced role of Rho-kinase to contraction ex vivo and airway resistance in vivo. In addition, we observed a difference in Rho-kinase dependency for histamine-and PGF 2 -induced contraction. Rho-kinase-inhibition affected potency and E max of PGF 2 -induced contraction in control preparations, which corresponds to observations by Ito et al (2003) in vascular smooth muscle, indicating that Rho-kinase plays an essential role in prostaglandin F 2 -induced contraction. Treatment with Y-27632 had no effect on potency and E max of histamine-induced contraction in control preparations, suggesting that under control situations these parameters are independent of Rho-kinase. However, treatment with Y-27632 did decrease contraction at the lower part of the CRC, indicating a contribution of Rho-kinase to contraction induced by low concentrations of histamine. This fully corresponds with our finding that Rho-kinase inhibition results in a decreased airway responsiveness to histamine in vivo, both in control and OA-sensitized animals, since the lower part of the CRC most likely represents the relevant in vivo concentrations of histamine. Mansour & Daniel (1987) reported that in guinea pig tracheal smooth muscle LTD 4 induced a significantly increased maximal contraction after sensitization, while contractile responsiveness toward other agonists tested did not alter markedly after OAsensitization. This supports our findings that the Rho-kinase dependent component of contraction is increased after sensitization, since leukotrienes are strongly dependent on Rho-kinase for contraction [30] .
The OA-sensitization-induced increase in potency of histamine and PGF 2 was normalized in the presence of Y-27632, indicating that this increased potency is caused by an enhanced contribution of Rho-kinase. Since MLCK is upregulated after sensitization [15, 31, 32] , suppression of Rho-kinase mediated inhibition of MLCP-activity would result in a more pronounced effect, because the level of MLCphosphorylation is governed by the ratio of MLCK and MLCP activities [2] .
An increased functional role of Rho-kinase might involve the small G-protein RhoA, which has been established to be one of the main upstream activators of Rho-kinase in (airway) smooth muscle [2] [3] [4] 33] . Others have shown elevated bronchial protein levels of RhoA [17] and increased RhoA translocation [34] in repeatedly challenged airwayhyperreactive rats. We observed that active allergic sensitization by itself is sufficient to induce an increase in RhoA expression, which might explain the enhanced functional contribution of Rho-kinase to airway responsiveness after OA-sensitization both in vitro and in vivo. The mechanisms underlying this augmented contribution of the Rho/Rhokinase signaling pathway after active allergic sensitization are currently unknown.
Recent work from our laboratory already showed that Rho-kinase is a major regulator involved in the basal maintenance of contractility in bovine tracheal smooth muscle [23] [Chapter 6]. We concluded that long-term inhibition of Rho-kinase might be beneficial for treatment of airway diseases, as this will result in a less contractile airway smooth muscle state without the induction of a proliferative phenotype. In addition, Y-27632 inhalation inhibited acetylcholine-and OA-induced increases in lung resistance in passively sensitized guinea pigs [35] . These findings suggest that there might be an essential role for Rho-kinase in airway hyperreactivity. Furthermore, our present findings indicate that Rho-kinase might be involved in the degree (and perhaps the development) of airway hyperreactivity, in view of the observation that the sensitization induced increase in potency of histamine and PGF 2 is reverted in the presence of Y-27632.
In conclusion, this study shows that the process of active allergic sensitization by itself without subsequent exposure to allergen, is capable of altering the contractile mechanism in guinea pig airway smooth muscle. This is explained by an enhanced contribution of Rho-kinase to airway smooth muscle contraction, presumably involving an increased expression of RhoA. Since increased airway responsiveness to bronchospasmogenic stimuli is a characteristic feature of asthma [36] , inhibition of the RhoA/Rho-kinase pathway may be considered useful as pharmacotherapeutical target in allergy and asthma.
